

Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma

Tamer Othman,¹ Paul Frankel,² Pamela Allen,³ Leslie L. Popplewell,¹ Geoffrey Shouse,¹ Tanya Siddiqi,¹ Alexey V. Danilov,¹ Nora Ruel,² Shari Daniels,¹ Lacolle Peters,¹ Stella Khoo,¹ Steven T. Rosen,¹ Elad Sharon,⁴ Miguel Villalona-Calero,⁵ Christopher Ruel,² Joseph Tuscano⁶ and Alex F. Herrera¹

¹Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA; ²Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA; ³Winship Cancer Institute at Emory University, Decatur, GA; ⁴Division of Cancer Treatment and Diagnosis, National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, MD; ⁵Department of Medical Oncology & Therapeutics Research, City of Hope National Cancer Center, Duarte, CA and ⁶Department of Internal Medicine, Division of Malignant Hematology, Cellular Therapy and Transplantation, University of California Davis School of Medicine, Sacramento, CA, USA

Correspondence: A.F. Herrera
aherrera@coh.org

Received: January 29, 2024.
Accepted: July 10, 2024.
Early view: July 18, 2024.

<https://doi.org/10.3324/haematol.2024.285185>

©2025 Ferrata Storti Foundation
Published under a CC BY-NC license



Supplementary Table 1: Adverse events through all courses for the 11 patients who proceeded to maintenance

Adverse Event	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
WHITE BLOOD CELL COUNT DECREASED	---	---	1(9%)	1(9%)	---
NEUTROPHIL COUNT DECREASED	---	1(9%)	---	1(9%)	---
LYMPHOCYTE COUNT DECREASED	1(9%)	---	3(27%)	---	---
HYPERTENSION	---	2(18%)	2(18%)	---	---
PLATELET COUNT DECREASED	4(36%)	---	2(18%)	---	---
ALT	3(27%)	1(9%)	1(9%)	---	---
ANEMIA	1(9%)	1(9%)	1(9%)	---	---
PERIPHERAL SENSORY NEUROPATHY	2(18%)	1(9%)	---	---	---
COUGH	1(9%)	1(9%)	---	---	---
FEVER	---	1(9%)	---	---	---
GASTROESOPHAGEAL REFLUX DISEASE	---	1(9%)	---	---	---
INFUSION RELATED REACTION	---	1(9%)	---	---	---
FATIGUE	5(45%)	---	---	---	---
HYPERGLYCEMIA	3(27%)	---	---	---	---
NAUSEA/VOMITING	3(27%)	---	---	---	---
PRURITUS	3(27%)	---	---	---	---
ALKALINE PHOSPHATASE INCREASED	2(18%)	---	---	---	---
BLOOD LACTATE DEHYDROGENASE INCREASED	2(18%)	---	---	---	---
COLD INTOLERANCE	2(18%)	---	---	---	---
CONSTIPATION	2(18%)	---	---	---	---
GGT INCREASED	2(18%)	---	---	---	---
MYALGIA	2(18%)	---	---	---	---
BLOOD BILIRUBIN INCREASED	1(9%)	---	---	---	---
CREATININE INCREASED	1(9%)	---	---	---	---
DIARRHEA	1(9%)	---	---	---	---
DRY SKIN	1(9%)	---	---	---	---
DYSGEUSIA	1(9%)	---	---	---	---
FLATULENCE	1(9%)	---	---	---	---
GENERALIZED MUSCLE WEAKNESS	1(9%)	---	---	---	---
HEADACHE	1(9%)	---	---	---	---
HYPOALBUMINEMIA	1(9%)	---	---	---	---
HYPONATREMIA	1(9%)	---	---	---	---
HYPOPHOSPHATEMIA	1(9%)	---	---	---	---

Adverse Event	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
INSOMNIA	1(9%)	---	---	---	---
MALAISE	1(9%)	---	---	---	---
PALPITATIONS	1(9%)	---	---	---	---
PROTEINURIA	1(9%)	---	---	---	---
TREMOR	1(9%)	---	---	---	---

